10-Q: Azenta Q3 2025: Divestiture Drives Net Loss Amidst Operational Gains

Azenta, Inc. reported a significant net loss for Q3 2025, primarily due to a substantial loss from discontinued operations, despite improvements in gross margin and reduced operating losses from continuing operations.

Summary

• Reported a net loss of $52.8 million for the three months ended June 30, 2025, a significant increase from a net loss of $6.6 million in the prior year period.
• The net loss was largely driven by a $53.5 million loss from discontinued operations, net of tax, for the three months ended June 30, 2025, which included a $68.8 million loss on assets held for sale related to the B Medical Systems business.
• Revenue from continuing operations was flat at $143.9 million for the three months ended June 30, 2025, compared to $144.3 million in the prior year period.
• Gross profit from continuing operations increased to $67.8 million (47% gross margin) for the three months ended June 30, 2025, up from $65.5 million (45% gross margin) in the prior year period, driven by operational efficiencies and favorable sales mix.
• Operating loss from continuing operations improved significantly to $0.7 million for the three months ended June 30, 2025, compared to an operating loss of $7.1 million in the prior year period.
• The Multiomics segment revenue increased by 4.1% to $66.2 million for the three months ended June 30, 2025, primarily due to growth in Next Generation Sequencing services.
• The Sample Management Solutions segment revenue decreased by 3.7% to $77.7 million for the three months ended June 30, 2025, due to lower revenue in Core Products, particularly Automated Stores and Cryogenic Systems.
• Cash provided by operating activities for the nine months ended June 30, 2025, was $70.0 million, a substantial increase from $32.2 million in the prior year period.
• Identified an additional material weakness in internal control over financial reporting related to the preparation and review of account reconciliations, which continues to exist as of June 30, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While continuing operations show some positive trends like improved gross margin and reduced operating loss, the significant net loss driven by the discontinued B Medical Systems business and the disclosure of ongoing material weaknesses in internal controls are substantial concerns. The overall financial picture is clouded by the divestiture's impact and internal control deficiencies, outweighing the operational efficiencies in core segments.

Positives

• Gross margin from continuing operations improved to 47% for the three and nine months ended June 30, 2025, up from 45% and 44% respectively, driven by operational efficiencies and favorable sales mix.
• Operating loss from continuing operations significantly decreased to $0.7 million for the three months ended June 30, 2025, compared to $7.1 million in the prior year period.
• Net cash provided by operating activities for the nine months ended June 30, 2025, increased to $70.0 million from $32.2 million in the prior year period, partly due to increased revenue collections and a $11.5 million U.S. federal tax refund.
• Multiomics segment revenue grew by 4.1% for the three months and 4.0% for the nine months ended June 30, 2025, driven by Next Generation Sequencing services.
• The company completed its $1.5 billion share repurchase authorization by September 30, 2024, indicating prior strong capital allocation to shareholders.

Negatives

• Reported a net loss of $52.8 million for the three months ended June 30, 2025, a significant increase from $6.6 million in the prior year period, primarily due to discontinued operations.
• Incurred a substantial loss of $53.5 million from discontinued operations, net of tax, for the three months ended June 30, 2025, including a $68.8 million loss on assets held for sale related to the B Medical Systems business.
• Income (loss) from continuing operations for the nine months ended June 30, 2025, was a loss of $26.9 million, a larger loss compared to $23.6 million in the prior year period.
• Interest income, net, decreased significantly to $5.0 million for the three months and $13.8 million for the nine months ended June 30, 2025, compared to $7.9 million and $27.4 million respectively, due to decreased investments in marketable securities.
• Sample Management Solutions segment revenue decreased by 3.7% for the three months ended June 30, 2025, driven by lower Core Products revenue.
• Multiomics segment gross margin decreased by 465 basis points for the three months and 167 basis points for the nine months ended June 30, 2025, primarily due to lower revenue from Gene Synthesis and Sanger sequencing services.
• Total selling, general and administrative expenses increased by $2.9 million for the nine months ended June 30, 2025, due to higher stock-based compensation and one-time costs related to leadership changes.

Risks

• Material weaknesses in internal control over financial reporting, specifically regarding cash flow statement review and account reconciliation preparation and review, which could lead to material misstatements.
• Uncertainty regarding the ultimate outcome of the Edwards Vacuum LLC claim for uncovered amounts related to the sale of the semiconductor cryogenics business, which could have a material adverse effect on consolidated financial position or results of operations.
• Exposure to general economic conditions, including the impact of inflation and tariffs, which could affect revenue, costs, and profitability.
• Dependence on key suppliers or vendors, with potential impacts from supply chain disruptions.
• Increased cybersecurity risks, including those resulting from employees working remotely.
• Ability to retain, hire, and integrate skilled personnel in a competitive life sciences industry.
• Fluctuations in foreign currency exchange rates, particularly in Germany, the United Kingdom, and China, affecting transactions and balances denominated in non-functional currencies.

Future Outlook

The company anticipates entering into a definitive agreement to sell its B Medical Systems business by November 2025, aiming to simplify its portfolio and focus on core Sample Management Solutions and Multiomics segments. The 2024 transformation plan, focused on cost reduction and productivity improvement, is expected to be completed by the end of fiscal year 2025. The company expects to generate a U.S. book loss during fiscal year 2025 and anticipates a valuation allowance of $22 million against its U.S. net deferred tax assets. The 'One Big Beautiful Bill Act' signed into US tax law is not expected to have a significant near-term effect on the effective tax rate or cash flows.

Management Comments

• Management is focused on driving revenue growth and profitability in the core Sample Management Solutions and Multiomics segments by simplifying the company's portfolio through the planned divestiture of the B Medical Systems business.
• The increase in gross margin for continuing operations is attributed to operational efficiencies and a favorable sales mix.
• Cost reduction initiatives across the business, particularly in research and development, have contributed to decreased operating expenses.
• Management is committed to continuing to improve internal control over financial reporting and is implementing remediation plans for identified material weaknesses.

Industry Context

Azenta operates in the life sciences industry, providing biological and chemical compound sample exploration and management solutions. Its offerings, including sample management, automated storage, and genomic services (Multiomics), cater to pharmaceutical, biotechnology, and life sciences research institutions. The company's strategic divestiture of the B Medical Systems business reflects a broader industry trend towards specialization and focus on core competencies to drive profitability and market leadership in specific niches.

Management Changes

Corporate Governance

Legal Proceedings

• Edwards Vacuum LLC is seeking recovery from the company for claimed amounts purportedly not covered, or inadequately covered, by representation and warranty insurance related to the sale of the semiconductor cryogenics business (the 'Claim for Uncovered Amounts'). The company disputes liability and does not believe this claim will have a material adverse effect on its consolidated financial position or results of operations for continuing operations, but an adverse outcome could have a material adverse effect in particular periods.

Stakeholder Impact

• Shareholders: Experienced a significant net loss per share due to discontinued operations, but the company completed its $1.5 billion share repurchase program in the prior fiscal year. Ongoing material weaknesses in internal controls could impact investor confidence.
• Employees: Subject to ongoing restructuring actions as part of the 2024 transformation plan, which includes severance and related costs. Stock-based compensation is a notable component of employee remuneration.
• Customers: The company continues to provide sample management and multiomics solutions, with strategic focus on these core businesses following the planned divestiture.
• Creditors: The company had no outstanding debt on its balance sheet as of June 30, 2025, indicating a strong liquidity position from a debt perspective.
• Regulatory Authorities: The company is subject to SEC filing requirements and is addressing identified material weaknesses in internal controls over financial reporting.

Next Steps

• Enter into a definitive agreement to sell the B Medical Systems business by November 2025.
• Complete the activities included in the 2024 transformation plan by the end of fiscal year 2025.
• Continue to implement and monitor remediation plans for material weaknesses in internal control over financial reporting, particularly for cash flow statement review and account reconciliations.
• Monitor the financial impact of the 'One Big Beautiful Bill Act' on tax rates and cash flows.
• U.S. customs authorities are expected to issue final audit results for the tariff matter by the end of the fourth quarter of fiscal year 2025.

Key Dates

Recommendation

The company presents a mixed financial picture. While continuing operations show positive trends in gross margin expansion and reduced operating losses, the substantial net loss driven by the discontinued B Medical Systems business and the ongoing material weaknesses in internal controls are significant concerns. The planned divestiture aims to streamline the business, but its immediate impact is a large loss. Investors should hold to observe the successful execution of the divestiture, the remediation of internal control issues, and sustained profitability in the core segments before considering further investment. The current situation presents both strategic upside from focus and downside risks from operational and control deficiencies.

Keywords

Azenta, AZTA, Life Sciences, Sample Management, Multiomics, Genomics, Biotechnology, Pharmaceutical, SEC Filing, Quarterly Report, Financial Results, Divestiture, Internal Controls, Corporate Governance, Cryogenics, Automated Storage